UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/588,478	10/02/2006	Andrew D. Hamilton	Y03-104US Nat	6687
	7590 10/28/200 JDOL SAPONE, P.C.	EXAMINER		
714 COLORADO AVENUE			CHO, JENNIFER Y	
BRIDGE PORT, CT 06605-1601			ART UNIT	PAPER NUMBER
			1621	
			MAIL DATE	DELIVERY MODE
			10/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Action Occurrence	10/588,478	HAMILTON ET AL.			
Office Action Summary	Examiner	Art Unit			
	JENNIFER Y. CHO	1621			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1)⊠ Responsive to communication(s) filed on <u>10 Ju</u>	lv 2008.				
• • • • • • • • • • • • • • • • • • • •					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
		0 0.0. 2.0.			
Disposition of Claims					
 4) Claim(s) 1-4, 7-8, 13, 15, 18, 20, 22, 35-47 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-4,7,8,13,15,18,20,22 and 35-45 is/are rejected. 7) Claim(s) 46-47 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 					
Application Papers					
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

Art Unit: 1621

Detailed Action

Receipt is acknowledged of the Response filed 7/10/08.

The claim objections have been withdrawn. The applicant has amended the claimed language to overcome the objections.

The 35 U.S.C. 102 and 103(a) rejections have also been withdrawn. Applicant has amended the claim language so that the art fails to teach or suggest the present invention as set forth in amended claim 1.

The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claim 22 must been renumbered claim 23. This renumbered claim 23 has been cancelled by the Applicant. Previously numbered claims 23 to 47 must be renumbered claims 24 to 48.

Thus renumbered claims 1-4, 7-8, 13, 15, 18, 20, 22, 35-47 are pending in this application. Renumbered claims 5-6, 9-12, 14, 16-17, 19, 21, 23-34 are cancelled. Applicant should refer to this claim numbering in all future correspondences.

Claim Objections

Renumbered claims 46-47 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections – 35 USC 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Nishikawa et al. (JP 07082225).

The instant claims are drawn to terephthalamide peptidomimetic compounds represented by formula (1) as depicted in claim 1.

Nishikawa et al. teaches amino acid derivatives, including the following shown below:

Application/Control Number:

10/588,478 Art Unit: 1621 Page 4

Therefore this claim is fully met.

Claim Rejections - 35 USC 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-4, 7-8, 13, 15, 18, 20, 22, 35-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nishikawa et al. (JP 07082225).

The instant claims are drawn to terephthalamide peptidomimetic compounds represented by formula (1) as depicted in claim 1.

Nishikawa et al. teaches amino acid derivatives with the general formula 1, which have pharmaceutical application as inhibitors of metastasis (abstract). Nishikawa et al. also teaches the following species shown below:

Nishikawa et al. is deficient in that it does not exemplify alkoxy substitutents on the benzene ring.

However, it would be prima facie obvious to one of ordinary skill in the art at the time of the invention, to determine the appropriate chemical constituents from Nishikawa et al.'s genus structural limitations, including substituting an alkoxy group on the benzene ring, to arrive at Applicant's compounds. The prior art teaches the generic, while Applicant teaches the species. One of ordinary skill in the art would have been motivated to make permutations of the variable groups within Nishikawa et al.'s genus structure, with the reasonable expectation that the compounds would be useful to treat metastasis. Absent any unusual and/or unexpected results, it is the Examiner's position that the teaching of the generic concept is obvious over the teaching of Applicant's species, because the same product is produced and the art recognizes the species as

Art Unit: 1621

equivalent. The expected result would be the efficient production of terephthalamide peptidomimetic compounds for the pharmaceutical industry.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Y. Cho whose telephone number is (571) 272 6246. The examiner can normally be reached on 9 AM - 6 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Daniel Sullivan can be reached on (571) 272 0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/588,478

Art Unit: 1621

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Cho Patent Examiner Art Unit: 1621

> /SHAILENDRA - KUMAR/ Primary Examiner, Art Unit 1621